Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG,MOG-IgG,and seronegative neuromyelitis optica spectrum disorders

Abstract

Objective:

To evaluate the effectiveness and tolerance of mycophenolate mofetil (MMF) as a first-line treatment in neuromyelitis optica spectrum disorder (NMOSD).

Methods:

In all, 67 NMOSD patients treated by MMF as first-line therapy, from the NOMADMUS cohort were included. A total of 65 fulfilled 2015 NMOSD criteria, and 5 were myelin oligodendrocyte glycoprotein (MOG)-immunoglobulin G (IgG) positive. Effectiveness was evaluated on percentage of patients continuing MMF, percentage of patients free of relapse, pre- and post-treatment change in the annualized relapse rate (ARR), and Expanded Disability Status Scale (EDSS).

Results:

Among 67 patients, 40 (59.7%) continued treatment till last follow-up. A total of 33 (49.3%) were relapse-free. The median ARR decreased from one pre-treatment to zero post-treatment. Of 53 patients with complete EDSS data, the score improved or stabilized in 44 (83%; p < 0.05). Effectiveness was observed in aquaporin-4 (AQP4)-IgG (57.8% continued treatment, 46.7% relapse-free), MOG-IgG (3/5 continued treatment, 4/5 relapse-free), and seronegative NMOSD (64.7% continued treatment, 61.3% relapse-free). In 16 patients with associated steroids, 13 (81.2%) continued MMF till last follow-up versus 15 of 28 (53.6%) in the non-steroid group. Nine patients discontinued treatment for tolerability purpose.

Conclusion:

MMF showed effectiveness and good tolerability as a first-line therapy in NMOSD, whatever the AQP4-IgG status. Concomitant use of oral steroids at start could limit the risk of treatment failure.

Keywords

Aquaporin-4 neuromyelitis optica treatment response myelin oligodendrocyte glycoprotein

Get full access to this article

View all access options for this article.

References

Lennon

Wingerchuk

Kryzer

et al . A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004; 364(9451): 2106–2112.

Lennon

. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202(4): 473–477.

Papadopoulos

Verkman

. Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012; 11(6): 535–544.

Misu

Höftberger

Fujihara

et al . Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol 2013; 125(6): 815–827.

Wingerchuk

Banwell

Bennett

et al . International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85(2): 177–189.

Wingerchuk

Lennon

Weinshenker

et al . The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6(9): 805–815.

Marignier

Bernard-Valnet

Giraudon

et al . Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivity-dependent entity. Neurology 2013; 80(24): 2194–2200.

Sato

Callegaro

Lana-Peixoto

et al . Seronegative Neuromyelitis Optica Spectrum—The challenges on disease definition and pathogenesis. Arq Neuropsiquiatr 2014; 72(6): 445–450.

Kitley

Waters

Leite

et al . Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: A comparative study. JAMA Neurol 2014; 71(3): 276–283.

10.

Kimbrough

Fujihara

Jacob

et al . Treatment of neuromyelitis optica: Review and recommendations. Mult Scler Relat Disord 2012; 1(4): 180–187.

11.

Pittock

Lennon

Mandrekar

et al . Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: An open-label pilot study. Lancet Neurol 2013; 12(6): 554–562.

12.

Araki

Matsuoka

Miyamoto

et al . Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study. Neurology 2014; 82(15): 1302–1306.

13.

Tradtrantip

Zhang

Saadoun

et al . Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 2012; 71(3): 314–322.

14.

Androdias

Maillet

Marignier

et al . Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology 2011; 76(13): 1168–1172.

15.

Jacob

Matiello

Weinshenker

et al . Treatment of neuromyelitis optica with mycophenolate mofetil: Retrospective analysis of 24 patients. Arch Neurol 2009; 66(9): 1128–1133.

16.

Huh

Kim

Hyun

et al . Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol 2014; 71(11): 1372–1378.

17.

Mealy

Wingerchuk

Levy

et al . Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: Multicenter study of treatment efficacy. JAMA Neurol 2014; 71(3): 324–330.

18.

Höftberger

Sepulveda

Armangue

. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Neurology 2015; 21(7): 866–874.

19.

Collongues

Papeix

Marignier

et al . Nosology and etiologies of acute longitudinally extensive transverse myelitis. Rev Neurol 2014; 170(1): 6–12.

20.

Tackley

O’Brien

Palace

et al . Neuromyelitis optica relapses: Race and rate, immunosuppression and impairment. Mult Scler Relat Disord 2016; 7: 21–25.

21.

Chiarelli

Molinaro

Libetta

et al . Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy. Brit J Clin Pharmaco 2010; 69(1): 38–50.

22.

Sombogaard

Peeters

Baan

et al . Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetil treated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not. Ther Drug Monit 2009; 31(5): 549–556.

23.

Cree

Lamb

Genain

et al . An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64(7): 1270–1272.

24.

Kim

et al . Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011; 68(11): 1412–1420.

25.

Mandler

Ahmed

Dencoff

. Devic’s neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998; 51(4): 1219–1220.

26.

Costanzi

Matiello

Lucchinetti

et al . Azathioprine tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011; 77(7): 659–666.

27.

Sellner

Boggild

Clanet

et al . EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010; 17(8): 1019–1032.

28.

Trebst

Jarius

Berthele

et al . Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261(1): 1–16.

29.

Jeong

Park

Kim

et al . Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler 2016; 22: 329–339.

30.

Jarius

Ruprecht

Kuempfel

et al . Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflamm 2012; 9(1): 14.

31.

Bernard-Valnet

Liblau

Vukusic

et al . Neuromyelitis optica: A positive appraisal of seronegative cases. Eur J Neurol. Epub ahead of print 16 February 2015. DOI: 10.1111/ene.12679.